Business
Supernus Announces Preliminary Second Quarter 2020 Revenue
Second quarter total revenue is estimated to be $126.7 million, a 21% increase over 2019Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be
About this update from Supernus Pharmaceuticals, Inc.
[{"type":"text","content":"Second quarter total revenue is estimated to be $126.7 million, a 21% increase over 2019Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be $113.4 million, an 11% increase over 2019Completed acquisition of CNS portfolio of US WorldMeds on June 9, 2020Management to host a conference call and webcast to review full second quarter 2020 results on Wednesday, August 19, 2020 at 9:00 a.m. ET ROCKVILLE, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported preliminary, unaudited revenue and net product sales for the second quarter of 2020.\n Preliminary second quarter 2020 revenue consisted of net product sales of $124.0 million and royalty revenue of $2.7 million. Preliminary second quarter 2020 net product sales of $124.0 million increased 21% compared to the same period in 2019 due to higher net product sales of Trokendi XR and Oxtellar XR and the addition of $10.6 million of net product sales from the acquisition of the CNS portfolio of US WorldMeds, which closed on June 9, 2020. Net Product Sales($ in millions) Q2 2020 Q2 2019 Change %Trokendi XR$89.7 $79.0 14%Oxtellar XR23.7 23.4 1%Acquired products110.6 — N/A Total$124.0 $102.4 21% 1 Acquired June 9, 2020. Includes APOKYN® pen, MYOBLOC® and XADAGO® The second quarter 2020 revenue results included herein are preliminary and are therefore subject to change. Conference Call Details The Company expects to report full second quarter 2020 results after 5:00 p.m. ET on Tuesday, August 18, 2020. The Company will hold a conference call hosted by Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Senior Vice President and Chief Financial Officer, to discuss these results at 9:00 a.m. Eastern Time, on Wednesday, August 19, 2020. Please refer to the information below for conference call dial-in information and webcast registration. Callers should dial in approximately 10 minutes prior to the start of the call. Conference dial-in:(877) 288-1043International dial-in:(970) 315-0267Conference ID:5175177Conference Call Name:Supernus Pharmaceuticals Second Quarter 2020 Earnings Conference Call Following the live call, a replay will be available on the Company's website, www.supe...